ALVO Q3’24 Earnings

Metric	Estimates	Actuals	Surprise
Revenue	$85.0M	$102.9M	BEAT by 21.0%
EPS	($0.06)	$0.00	BEAT by 100.0%

ALVO Historical Revenue & EPS and Expectations

10Y

Revenue

EPS

Actual Revenue

Forecast Revenue

ALVO Earnings History

	Mar'19	Jun'19	Sep'19	Dec'19	Mar'20	Jun'20	Sep'20	Dec'20	Mar'21	Jun'21	Sep'21	Dec'21	Mar'22	Jun'22	Sep'22	Dec'22	Mar'23	Jun'23	Aug'23	Dec'23	Mar'24	Jun'24	Sep'24
Revenue actual	$7,979.5K	$7,979.5K	$7,979.5K	$7,979.5K	$16.7M	$16.7M	$16.7M	$16.7M	$1,178.0K	$1,178.0K	$536.0K	$34.8M	$452.0K	$39.7M	$19.1M	$23.9M	$15.9M	$4,391.0K	$17.8M	$53.4M	$12.4M	$198.8M	$102.9M
Revenue estimate	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	$42.0M	$42.0M	$93.0M	$93.0M	$198.8M	$85.0M
Revenue surprise	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	89.5%	57.6%	42.6%	86.6%	0.0%	21.0%
EPS actual	($0.22)	($0.22)	($0.22)	($0.22)	($0.17)	($0.17)	($0.17)	($0.30)	$0.23	($0.01)	($0.41)	$1.28	($0.32)	($0.54)	($0.04)	($1.29)	($1.05)	$0.72	($0.70)	($1.04)	($0.82)	$0.25	$0.00
EPS estimate	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	($0.14)	($0.14)	$0.04	$0.04	$0.00	($0.06)
EPS surprise	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	614.3%	400.0%	2,576.2%	2,052.4%	8,233.3%	100.0%

ALVO Price Change after Earnings

Crunching data... Almost there!

ALVO Recent Quarter Financial Statements Overview

Income statement

Balance sheet

Cash Flow statement

Revenue

$102.9M 478.4% YoY

Gross profit

$63.1M 0.0% YoY

61.3% margin

Cost of revenue

$39.8M 9.0% YoY

Operating income

$12.7M 0.0% YoY

12.4% margin

Other: $24.2M

Net interest: $13.3M

Operating expenses

$50.3M (27.9%) YoY

Pre-tax income

$24.8M (88.0%) YoY

(24.1%) margin

Net income

$11.4M (94.0%) YoY

(11.1%) margin

R&D

$33.6M (36.9%) YoY

32.6% of revenue

SG&A

$16.9M 1.4% YoY

16.4% of revenue

Competing with ALVO Earnings

Overview

Ratings

Intrinsic Value

Valuation

Growth

Profitability

Health

Capital allocation

Momentum

Earnings

Dividends

Company name	Market Cap	Revenue	EPS	Last quarter Revenue growth	Last quarter EPS growth	Last quarter Revenue surprise	Last quarter EPS surprise	Next quarter Revenue growth	Next quarter EPS growth	Last 10 Earnings (how many miss vs beat)	1Y Fwd Revenue growth	1Y Fwd EPS growth
AlvotechALVO ALVO	$2,990.3M	$367.5M	($1.61)	478.4%	(100.0%)	undefinedN/A	undefinedN/A	(15.0%)	0.0%	Beats: 2 Misses: 4	397.0%	(88.7%)
Zoetis Inc.ZTS ZTS	$74.1B	$9,256.0M	$5.47	4.7%	12.3%	Beat by 1.2%	Miss by 12.1%	(5.2%)	10.5%	Beats: Misses:	1.3%	12.0%
Takeda Pharmaceutical Company LimitedTAK TAK	$47.5B	¥4,546.1B	¥184.31	12.7%	N/A	Beat by 14.4%	Beat by 183.7%	(19.6%)	(76.4%)	Beats: 7 Misses: 3	(3.5%)	(51.6%)
Haleon plcHLN HLN	$46.7B	£11.2B	£4.71	(0.3%)	N/A	Miss by 59.4%	Miss by 86.5%	19.3%	287.8%	Beats: 2 Misses: 7	23.4%	217.9%
Teva Pharmaceutical Industries LimitedTEVA TEVA	$18.3B	$16.6B	($1.45)	(5.1%)	N/A	Beat by 2.2%	Miss by 128.7%	(5.8%)	(360.0%)	Beats: 6 Misses: 4	3.6%	(275.8%)
Intra-Cellular Therapies, Inc.ITCI ITCI	$13.6B	$680.6M	($0.73)	51.5%	(46.7%)	Beat by 15.6%	Miss by 10.7%	2.6%	(46.1%)	Beats: 7 Misses: 3	37.8%	(191.5%)
Neurocrine Biosciences, Inc.NBIX NBIX	$11.6B	$2,355.3M	$3.38	21.8%	(31.3%)	Beat by 4.5%	Miss by 31.6%	(4.0%)	(16.8%)	Beats: 2 Misses: 8	13.6%	24.6%
Catalent, Inc.CTLT CTLT	$11.6B	$4,422.0M	($2.26)	4.2%	(82.0%)	Miss by 16.4%	Miss by 252.1%	8.0%	(118.2%)	Beats: 4 Misses: 6	5.6%	(118.6%)
Dr. Reddy's Laboratories LimitedRDY RDY	$11.4B	₹311.3B	₹64.41	15.9%	2.4%	Beat by 8.4%	Miss by 2.2%	(1.6%)	6.6%	Beats: 7 Misses: 3	14.8%	0.8%
Viatris Inc.VTRS VTRS	$11.1B	$14.7B	($0.52)	(8.1%)	(32.8%)	Miss by 5.0%	Miss by 163.5%	(6.4%)	(219.8%)	Beats: 5 Misses: 5	(6.6%)	(531.1%)